These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 25301170)

  • 21. Inhibition of protein tyrosine phosphatase-1B with antisense oligonucleotides improves insulin sensitivity and increases adiponectin concentrations in monkeys.
    Swarbrick MM; Havel PJ; Levin AA; Bremer AA; Stanhope KL; Butler M; Booten SL; Graham JL; McKay RA; Murray SF; Watts LM; Monia BP; Bhanot S
    Endocrinology; 2009 Apr; 150(4):1670-9. PubMed ID: 19164474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consequences of the inhibition of Hdm2 expression in human osteosarcoma cells using antisense oligonucleotides.
    Geiger T; Hüsken D; Weiler J; Natt F; Woods-Cook KA; Hall J; Fabbro D
    Anticancer Drug Des; 2000 Dec; 15(6):423-30. PubMed ID: 11716435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I trial of ISIS 104838, a 2'-methoxyethyl modified antisense oligonucleotide targeting tumor necrosis factor-alpha.
    Sewell KL; Geary RS; Baker BF; Glover JM; Mant TG; Yu RZ; Tami JA; Dorr FA
    J Pharmacol Exp Ther; 2002 Dec; 303(3):1334-43. PubMed ID: 12438559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Integrated Safety Assessment of 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides in NonHuman Primates and Healthy Human Volunteers.
    Crooke ST; Baker BF; Kwoh TJ; Cheng W; Schulz DJ; Xia S; Salgado N; Bui HH; Hart CE; Burel SA; Younis HS; Geary RS; Henry SP; Bhanot S
    Mol Ther; 2016 Oct; 24(10):1771-1782. PubMed ID: 27357629
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro metabolic stabilities and metabolism of 2'-O-(methoxyethyl) partially modified phosphorothioate antisense oligonucleotides in preincubated rat or human whole liver homogenates.
    Baek MS; Yu RZ; Gaus H; Grundy JS; Geary RS
    Oligonucleotides; 2010 Dec; 20(6):309-16. PubMed ID: 21117960
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100.
    Yu RZ; Kim TW; Hong A; Watanabe TA; Gaus HJ; Geary RS
    Drug Metab Dispos; 2007 Mar; 35(3):460-8. PubMed ID: 17172312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
    Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
    Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
    Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
    J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of 2'-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides.
    Masaki Y; Iriyama Y; Nakajima H; Kuroda Y; Kanaki T; Furukawa S; Sekine M; Seio K
    Nucleic Acid Ther; 2018 Oct; 28(5):307-311. PubMed ID: 30020852
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.
    Henry SP; Miner RC; Drew WL; Fitchett J; York-Defalco C; Rapp LM; Levin AA
    Invest Ophthalmol Vis Sci; 2001 Oct; 42(11):2646-51. PubMed ID: 11581212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing in vitro and in vivo activity of 2'-O-[2-(methylamino)-2-oxoethyl]- and 2'-O-methoxyethyl-modified antisense oligonucleotides.
    Prakash TP; Kawasaki AM; Wancewicz EV; Shen L; Monia BP; Ross BS; Bhat B; Manoharan M
    J Med Chem; 2008 May; 51(9):2766-76. PubMed ID: 18399648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.
    Henry SP; Templin MV; Gillett N; Rojko J; Levin AA
    Toxicol Pathol; 1999; 27(1):95-100. PubMed ID: 10367680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
    Senn JJ; Burel S; Henry SP
    J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complement activation is responsible for acute toxicities in rhesus monkeys treated with a phosphorothioate oligodeoxynucleotide.
    Henry SP; Beattie G; Yeh G; Chappel A; Giclas P; Mortari A; Jagels MA; Kornbrust DJ; Levin AA
    Int Immunopharmacol; 2002 Nov; 2(12):1657-66. PubMed ID: 12469940
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preclinical evaluation of the effects of a novel antisense compound targeting C-raf kinase in mice and monkeys.
    Monteith DK; Geary RS; Leeds JM; Johnston J; Monia BP; Levin AA
    Toxicol Sci; 1998 Dec; 46(2):365-75. PubMed ID: 10048140
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
    Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
    Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.
    Younis HS; Crosby J; Huh JI; Lee HS; Rime S; Monia B; Henry SP
    Blood; 2012 Mar; 119(10):2401-8. PubMed ID: 22246038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.